Idecabtagene Vicleucel

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. “We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. “Noah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers.” As Chief Medical Officer of Arvinas Pharmaceuticals, Dr. Berkowitz led the clinical strategy that resulted in the first-ever U.S. Food and Drug Administration (FDA) approval of a targeted protein degradation therapy and expanded the company’s clinical programs across cancer, neurological, and rare diseases. Previously, Dr. Berkowitz served as Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb, where he oversaw the full scope of drug development for the company’s benign and malignant hematology programs and, on an interim basis, its cell therapy programs. His global development teams achieved regulatory approvals for the chimeric antigen receptor (CAR) T cell therapies Abecma and Breyanzi, two of the first cell therapies approved for multiple myeloma and large B cell lymphoma, respectively. Clinical programs under his leadership helped drive recent annual sales of Reblozyl above $2 billion. Earlier, Dr. Berkowitz held leadership positions of increasing responsibility in clinical development across multiple cancer indications at Novartis. Dr. Berkowitz completed a clinical investigation fellowship in medical oncology at the National Cancer Institute (NCI). He holds an M.D. and Ph.D. in molecular immunology from Columbia University. “I am excited to join Iovance at this critical inflection point to explore broader applications for TIL technology in new indications and treatment settings,” stated Dr. Berkowitz. “The Iovance TIL platform demonstrates remarkable clinical results and represents the new frontier across solid tumors, including next-generation approaches. I look forward to contributing to the Iovance vision to expand the reach of this transformative treatment to patients who need it most.” In connection with Dr. Berkowitz’s appointment, Iovance approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 450,000 shares of Iovance’s common stock to Dr. Berkowitz. The awards were granted on September 30, 2026 (the date of grant), under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted has an exercise price of $14.82, the closing price of Iovance’s common stock on the date of grant. Each stock option and each restricted stock unit vests over a three-year period, with one-third of the shares vesting on the first anniversary of Dr. Berkowitz’s start date (the first vesting date) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the first vesting date. In addition, certain of these restricted stock units may vest upon the achievement of performance milestones based on specified regulatory results rather than time-based vesting. The foregoing vesting is subject to continued employment with Iovance through the applicable vesting dates. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (li ) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit . Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on . Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. CONTACTS Investors IR@iovance.com 650-260-7120 ext. 150 Media PR@iovance.com 650-260-7120 ext. 150

Biotech industry veteran with two decades of clinical development, manufacturing, and technical operations leadership to guide ImmunoScape's "Seed and Boost" platform toward the clinic SINGAPORE & BOSTON--(BUSINESS WIRE)-- ImmunoScape Pte. Ltd. , an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the appointment of Peter Olagunju as Chief Executive Officer. Olagunju joins ImmunoScape as the company prepares to advance its Seed and Boost platform into the clinic. Co-founder Michael Fehlings, Ph.D., continues to lead the company's scientific and technical strategy as Chief Technology Officer. “Peter is the rare executive who has done this at every stage: building manufacturing platforms from academic starting points, guiding products through regulatory approval, and running a company from formation through successful outcomes. He has helped bring seven therapies to commercialization and knows how to build lean, capital-efficient organizations,” said Adrian Bot, MD, Ph.D., ImmunoScape Board Member and former Chief Scientific Officer of both Kite Pharma and Capstan Therapeutics. “As ImmunoScape moves from platform to clinic, that combination of technical depth and operating judgment is precisely what the company needs.” Olagunju brings more than 20 years of experience in clinical development, manufacturing, and technical operations, and has contributed to seven approved products, including PROVENGE ® , ZYNTEGLO ® , ABECMA ® , ADSTILADRIN ® , SKYSONA ® , and LYFGENIA ® . He most recently served as Chief Executive Officer of a Catalio Capital-backed oncology company, which he led from formation through a $14 million seed financing to a successful corporate transaction. He previously held Chief Operating Officer and Chief Technology Officer roles at TCR² Therapeutics, where he served as the operations lead on the company's acquisition by Adaptimmune, and has held senior executive positions at FerGene and bluebird bio. Olagunju is Chairman of the Board of March Biosciences and holds an M.B.A. from the University of Washington's Foster School of Business and a B.S. in Biology from the University of Illinois at Urbana-Champaign. “Solid tumors have been the hardest problem in cell therapy, and the limiting factor has consistently been persistence — getting engineered T cells to survive and keep working inside the tumor,” said Olagunju. “ImmunoScape’s Seed-and-Boost approach goes directly at that problem, and it does so with a platform that applies across autologous, allogeneic, and in vivo delivery. I’ve spent my career translating academic science into manufacturing and clinical execution at scale, and that is exactly what this moment calls for. My immediate priority is working with our partners to move our platform into the clinic.” About ImmunoScape ImmunoScape is a premier, clinical-stage Singapore-headquartered biotechnology company focused on the discovery and development of next-generation cell immunotherapies in oncology. With operations in Singapore and Boston, ImmunoScape drives innovation to deliver transformative treatments for solid tumors using its proprietary deep immunomics and high-throughput TCR discovery platforms. For more information, please visit immunoscape.com . Contacts Media Kalyn Schieffer for ImmunoScape kos@anzupartners.com